The Integrum project is a program intended to develop new therapeutic antibodies for all therapeutic targets.
BEIJING and BOSTON, Sept. 25, 2020 / PRNewswire / – Beijing Biocytogen Biotechnology Co. (“Biocytogen”) announced in August the acquisition of Eucure Biopharma, which has made Biocytogen a clinical stage company. Today, Biocytogen is pleased to announce the closing of a Series D1 funding round, which raised US $ 142 million to secure the implementation of the Integrum project.
The Integrum project is a humanitarian effort aimed at discovering, developing and bringing to the market novel therapeutic antibody candidates against all notoriously difficult therapeutic targets. Taking full advantage of Biocytogen’s integrated technology platforms for antibody discovery, the Integrum project will launch preclinical efforts addressing more than 1,000 human diseases that currently affect countless lives.
Meticulous screening for candidate antibodies in vivo and in vitro improve clinical translationality. At the heart of Biocytogen is the humanized RenMab Mouse antibody and a plethora of advanced and proprietary gene targeting strategies, which have been fully optimized and integrated with the most advanced complementary technologies in the express purpose of discovering clinically relevant therapeutic antibodies. from a clinical point of view.
Whether through knockout mice targeted on RenMab, personalized humanized target mouse models, pharmacological screening tests in vivo or even translational medicine for companion dogs, Biocytogen is committed to finding antibodies with clinical translational value. Dr Yuelei Shen, Chairman and CEO of Biocytogen, said: “The funds raised during this ongoing round support a rapid implementation of the development of RenMab mouse knockout models for a large number of targets in immuno-oncology and autoimmune diseases, and for difficult targets, in particular ion channels and GPCR proteins, and other strong human-mouse homologies ”.
With its extensive experience and knowledge, Biocytogen can help identify which antibody candidates have the best chance of clinical success, based on the level of cross-reactivity between species. The Integrum project was established to unite doctors, researchers and scientists across borders in a collective effort to make Biocytogen an original source of future treatments. Promising to pursue scientific advances and to expand its collaborations in the development of innovative drugs, Biocytogen welcomes new partnerships with biotechnology and pharmaceutical companies around the world.
We would like to thank CMB International, the main investor in this round, and our investor partners PICC Capital, SDIC Ventures, China Life Equity, 3E Bioventures, Cowin Capital and Baifu Capital.
Biocytogen is a global biotechnology company specializing in the research and development of new drugs through innovative technologies. Biocytogen works in collaboration with international partners to accelerate the discovery and development of new drugs.
Contact : [email protected]